Chatziralli Irini, Agapitou Chrysa, Dimitriou Eleni, Kapsis Petros, Kazantzis Dimitrios, Risi-Koziona Alexia, Theodossiadis Georgios, Theodossiadis Panagiotis
Second Department of Ophthalmology, National and Kapodistrian University of Athens, Athens, GRC.
Cureus. 2024 Aug 11;16(8):e66638. doi: 10.7759/cureus.66638. eCollection 2024 Aug.
The purpose of this study is to investigate the prevalence of vitreoretinal interface (VRI) disorders in patients with retinal vein occlusion (RVO) and to evaluate the impact of VRI abnormalities on the treatment outcomes of macular edema secondary to RVO using intravitreal aflibercept.
Participants in this prospective study were consecutive patients with macular edema secondary to RVO, who received intravitreal aflibercept injections. At baseline, best-corrected visual acuity (BCVA) was assessed, and spectral domain-optical coherence tomography (SD-OCT) was performed to measure central subfield thickness (CST) and to evaluate the presence of VRI disorders, namely, vitreoretinal adhesion (VMA), vitreoretinal traction (VMT), epiretinal membrane (ERM), lamellar macular hole (LMH), and full-thickness macular hole (FTMH). The primary outcomes were the prevalence of various VRI disorders in patients with RVO and the impact of VRI disorders on BCVA and CST after aflibercept treatment in such patients.
At baseline, 16.1% of patients had VMA, 3.2% VMT, 18.3% ERM, and 1.1% LMH. There were a statistically significant improvement in BCVA and a decrease in CST in RVO patients over time. There was no statistically significant difference regarding BCVA and CST at baseline and until month 24 after treatment between patients with VRI disorders and those without VRI disorders. However, the mean number of injections during the follow-up period was higher in the group with VRI disorders (9.4±2.1) compared to those without VRI disorders (8.1±0.7, p=0.0002).
The prevalence of VRI disorders in patients with RVO was 16.1% for VMA, 3.2% for VMT, 18.3% for ERM, and 1.1% for LMH. VRI disorders were not found to affect the anatomical and visual outcomes after intravitreal aflibercept treatment in patients with RVO, although more intravitreal injections were needed in patients with VRI disorders.
本研究旨在调查视网膜静脉阻塞（RVO）患者玻璃视网膜界面（VRI）疾病的患病率，并评估VRI异常对使用玻璃体内阿柏西普治疗RVO继发黄斑水肿的治疗效果的影响。
本前瞻性研究的参与者为连续的RVO继发黄斑水肿患者，他们接受了玻璃体内阿柏西普注射。在基线时，评估最佳矫正视力（BCVA），并进行光谱域光学相干断层扫描（SD-OCT）以测量中心子野厚度（CST）并评估VRI疾病的存在，即玻璃体视网膜粘连（VMA）、玻璃体视网膜牵拉（VMT）、视网膜前膜（ERM）、黄斑板层裂孔（LMH）和黄斑全层裂孔（FTMH）。主要结局是RVO患者中各种VRI疾病的患病率以及VRI疾病对阿柏西普治疗此类患者后BCVA和CST的影响。
在基线时，16.1%的患者有VMA，3.2%有VMT，18.3%有ERM，1.1%有LMH。随着时间的推移，RVO患者的BCVA有统计学意义的改善，CST降低。在基线时以及治疗后直至24个月，有VRI疾病的患者与无VRI疾病的患者在BCVA和CST方面没有统计学意义的差异。然而，随访期间有VRI疾病的组的平均注射次数（9.4±2.1）高于无VRI疾病的组（8.1±0.7，p=0.0002）。
RVO患者中VRI疾病的患病率为VMA 16.1%、VMT 3.2%、ERM 18.3%、LMH 1.1%。尽管有VRI疾病的患者需要更多的玻璃体内注射，但未发现VRI疾病会影响RVO患者玻璃体内阿柏西普治疗后的解剖和视觉结局。
